The latest ROE for DFFN is -132.18%. That is below the Healthcare sector average of 20.77%. Investors often review this figure alongside Diffusion Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, DFFN currently prints -132.18% for ROE, while the sector average sits near 20.77%. That is roughly 736.5% below the sector mean. Large gaps often invite a closer look at Diffusion Pharmaceuticals's growth, margins, and balance sheet.

Return on Equity shows how effectively Diffusion Pharmaceuticals converts resources into returns. At -132.18%, DFFN may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting DFFN's ROE (-132.18%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Diffusion Pharmaceuticals's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.